A investor's eulogy for Quartet Medicine: founded back in 2013, this biotech aspired to address neuropathic and inflammatory pain via a novel biologic mechanism. Unfortunately, after 3 years of solid drug discovery, the startup is being shut down due to an unexpected safety signal. R.I.P. Quartet
from Forbes Real Time https://www.forbes.com/sites/brucebooth/2017/11/17/painful-truth-successful-failure-of-a-biotech-startup/
via IFTTT
No comments:
Post a Comment